Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast with teleconference, Q1'24

By Inderes5/16/2024, 8:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 03:26

Thank you and welcome, everyone, to the Q1 report for 2024. On this call, we will be making forward-looking statements. Today's call will start with a recap of the highlights and recent key events. This will be followed by a portfolio update before moving on to financials and priorities ahead. As mentioned, after the presentation, we will open up for questions. At Ascelia Pharma AB, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglance has now been advanced to the registration phase as we have successfully completed the pivotal Phase 3 clinical study. Oncoral has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million. Oncoral is ready to start Phase 2 in the treatment of gastric cancer, based on encouraging results in Phase 1 and a high level of unmet medical need. We are based in Malmö, Sweden, and are listed on Nasdaq Stockholm since 2019. In Q1, we made solid progress, which has been followed by a busy period after the close of the quarter. In the first quarter, the nomination committee was appointed, and the Orviglance Review article was published in Investigative Radiology. This is one of the highest-impact radiology medical journals. In February, we announced a financing of up to 35 million Swedish kronor, which extends our financial runway to next Q2 2025 if fully utilized. After the closing of the first quarter. We have announced a number of events in the first half of April. We announced the completion of Orviglance image reading by the independent readers and narrowing the timeline for the results to the first half of May. We also drew the second and final 15 million tranche of the formal financing. On the 2nd of May, we announced the strong headline result from the Orviglance study, making this study highly successful. We will talk a lot more about this on this call. A few days after the results, we had the annual general meeting, which was followed by the investor update bringing all the plans to patients. Orviglance met the primary endpoint in the study, making this study a success. It not only met the primary endpoint, it met it with a substantial margin. All three out of three readers met the endpoint. The success criteria was two out of three. All three readers evaluated Orviglance claims to be superior to an enhanced MRI, and statistical tests that P values lower than 0.001 for all readers on the primary endpoint. This is much lower than the customary threshold for p-value success. The conclusions are solid and the variability levels were acceptable. This is the most significant milestone in Ascelia Pharma's history, and a huge step forward towards making Orviglance available to patients. Once again, I'd like to thank patients, investigators, and everyone else who have contributed to making Orviglance a success.

Andreas Norlin
03:28 - 03:29

Today.

Magnus Corfitzen
03:29 - 05:08

We are very excited about all the coverage. And here is why: Orviglance addresses a well-defined unmet medical need for a subgroup of patients living with cancer. This is an $800 million global market opportunity, and Orviglance is the first-in-class product to target this. We have strong data from nine clinical studies, and manufacturing has been upscaled to commercial scale with strong Phase 3 data. Orviglance has now been advanced to the regulatory apex. We focus on three key objectives to create even more value for shareholders. The first objective is the timely submission and approval of Orviglance with the optimal label. The key steps along the way are completion of the clinical study report, which we expect in early Q4. It's also a key milestone with the conclusions from the pre-submission meeting that we plan to have with the FDA, and we expect to have the conclusion from the meeting in Q1 next year. Thus, the feedback from the FDA will be used to finalize the NDA submission, which is expected to be filed in the middle of next year. The second objective is to progress Orviglance for commercialization for patients in need. There are two key tracks. One is to continue to invest, advance the launch readiness by ensuring manufacturing and supply chains are ready for launch, as well as working with medical experts and key opinion leaders, payers, patient advocacy groups, and other key stakeholders.

Andreas Norlin
05:09 - 05:10

The other track.

Magnus Corfitzen
05:10 - 05:53

Here, we are entering into commercialization partnerships to make sure that there is an infrastructure in place, following approval, to ensure that Orviglance can actually get to all patients. The third objective is to develop the potential in the pipeline we're excited about Oncoral and the planned Phase 2 study, where we will evaluate Oncoral in combination with Oncoral. In our pipeline, we also have a second-generation Orviglance program that we would like to advance. Very limited activities are ongoing right now in our third track here, and we look forward to accelerating these activities once financing is available. Or no. There is tremendous potential in Ascelia Pharma to create value for shareholders.

Andreas Norlin
05:54 - 05:55

With this.

Magnus Corfitzen
05:55 - 06:09

I conclude the highlights of recent key events, and we will now move into the portfolio phase. We start the portfolio section with our presentation on Orviglance. And I'd like to hand over to Andreas to continue the presentation.

Andreas Norlin
06:13 - 11:05

Thank you, Magnus. Orviglance is a first-in-class liver MRI contrast agent, which addresses a very specific unmet medical need where there are no good alternatives available today. Cancer in the liver is a major problem in cancer treatment, and most cancers can deliver a metastasis where the tumor originates in another organ and spreads to the liver. Contrast-enhanced MRI is the gold standard procedure for examination of patients with suspected or known liver lesions, including metastasis. The most used contrast agents available are all based on the heavy metal gadolinium. In patients with severe kidney impairment. Use of gadolinium-based contrast agents has been associated with an increased risk of a very severe side effect called nephrogenic systemic fibrosis, which even may have a lethal outcome. Both the European and US regulatory authorities have, for that reason, issued warnings for the use of gadolinium-based contrast agents in this group of patients. The consequence is that patients with impaired kidney function typically will get an enhanced MRI, which will result in liver images of suboptimal quality, with the risk that cancer is not managed in the best possible way. We envision that Overglance, which is based on manganese, will address this unmet medical need in the future and become an efficacious non-gadolinium contrast agent for cancer patients with impaired kidney function. We have now obtained highly encouraging headline data from the Sparkle Phase 3 study, clearly demonstrating strong, superior enhancement of visualization of focal liver lesions with Orviglance compared to an enhanced MRI, as evidenced by p values lower than 0.001. The strength of the data is emphasized by the fact that all three independent readers who evaluated the efficacy in this study confirmed superiority of Orviglance. For the study to be successful, at least two of the three readers needed to observe a statistically significant improvement. With this in mind, the unanimous reporting of a highly significant effect makes the conclusion that Orviglance MRI is superior to an enhanced MRI very strong. Importantly, in light of the issues with inter-reader variability reported last year, the analysis of the data also showed an acceptable level of variability for all readers, making the analysis strong and conclusive. Common adverse events, primarily mild to moderate nausea, were in line with previous Phase 1 and 2 studies with regards, and no serious adverse drug reactions were observed. With Sparkle, we have a comprehensive package of clinical studies with consistent positive efficacy and safety data that will be used for the submission of the new drug application and a file for regulatory approval by the US FDA. A total of 286 patients and healthy volunteers in nine clinical studies will be included in the NDA file. We are aiming to submit a high-quality NDA to the FDA as soon as possible. Our goal is to secure approval for an optimal label, offering a new choice for patients who can't use gadolinium-based contrast agents for liver imaging today. With our comprehensive data package in hand, which includes the clinical data as well as non-clinical and chemistry and manufacturing data, we are now intensifying our preparations of the NDA file. Focus is to ensure that every aspect of Orviglance is thoroughly documented and presented, reflecting our anticipation of a successful review by the US FDA. We're on track to submit for NDA approval by mid-2025. And following the submission, we anticipate a standard ten-month review process by the FDA. On the way towards the NDA submission. We are looking forward to key milestones such as the delivery of the full study Sparkle report in early Q4 this year and the completion of the pre-NDA meeting with the FDA by Q1 2025. The pre-NDA meeting is a critical project in its own right, with a purpose to lay out the groundwork for the NDA submission. This ensures that we are on the same page as the FDA and will facilitate the seamless review process when we file the NDA. To wrap it up, with the strong headline data from Sparkle demonstrating superior imaging with Orviglance compared to an enhanced MRI. We are now advancing Orviglance into the registration phase. With that, I will hand over to Julie.

Julie Waras Brogren
11:07 - 18:27

Thank you, Andreas. So, the addressable market for Orviglance has a global value of $800 million annually. The US represents almost half of this. This market opportunity for Orviglance addresses the unmet need for a well-defined patient population. Cancer patients who need liver imaging and who also have severely impaired kidney function. Our strategy for commercialization is to launch through partners. This strategy supports our ambition to secure the optimal balance between future revenues and investment required. And it allows us to leverage commercial capabilities already established by a partner. Our focused, ambitious loan strategy and plans build on advanced market insights, and these are in place to support this partnering strategy and to support the launch. As mentioned, the US is the largest commercial opportunity in the US alone. Our real world data, i.e. data from realized procedures in our target patient population, show that every year a hundred thousand abdominal imaging procedures are performed in 50,000 patients that fall under the black box warning. For gadolinium contrast agents, this is about 4% of cancer patients that undergo abdominal imaging. The well-defined patient population with a clear unmet need also drives an attractive pricing opportunity. And we have extensive input from market access and pricing experts, with whom we tested different price levels and collected insights on the evidence needed to support access and reimbursement at launch. And we have also investigated pricing and access benchmarks for other innovative diagnostic drugs in the US. 90% of health care professionals are concerned with the issues related to gadolinium contrast agents, including nephrogenic systemic fibrosis, or NSF, as Andrea has mentioned. In fact, 16% of providers have experienced gadolinium-induced NSF. These insights come from market research, with 270 US healthcare professionals and answers from radiologists, nephrologists, and oncologists. And these insights confirm the concerns with gadolinium in clinical practice and the unmet need for Orviglance. When speaking to experts, whether in radiology or nephrology. They also confirm that an alternative to gadolinium for our target patient population would address concerns of today. Supporting the potential for Orviglance to become a valuable addition to clinical practice. In clinical practice, the unmet need for our target patient population is also well recognized. Physicians tell us that patients who need liver imaging and fall under the black box warning for gadolinium today receive MRIs that balance the trade-off between, on the one hand, being without a contrast agent, i.e. an inferior image quality, or by being a half dose scheduled in them. These are around 80% of the patients in total. Or by being with a full gadolinium dose, with the awareness that gadolinium is not recommended for these patients due to the black box warning. All of these patients are potential Orviglance patients. Beyond the risk of NSF in kidney impaired patients, gadolinium is well known to be retained in the brain and other tissues in all patients. And scrutiny over the possible safety effects is a key concern of regulators and medical bodies. It is also well known that gadolinium is excreted via the kidneys in urine, because it's difficult to remove in our sewage systems. This is discharged into the environment, even into our drinking water. So there is an urgency from regulators and medical bodies to find a viable alternative to the growing use of toxic gadolinium. And the answer to that is not associated with these potential safety and environmental concerns for patients and the environment with gadolinium. So, in short, the momentum for an alternative to gadolinium is getting better and better, and the industry is responding to this. Recent developments from large gadolinium manufacturers are focused on smaller doses of gadolinium, and thus even an early stage injectable manganese based contrast agent, which is not like, um. Not like all the claims because it's not liver specific. So we are excited that we have a head start, and that the upcoming weekend is expected to be a first in class to lead a future with less gadolinium and improved outcomes for our target patients. The go-to-market strategy for all the drugs is to launch with commercialization partners. This supports our objectives to secure the optimal balance between future revenues and investment required. And as mentioned, it also allows us to leverage the commercial capabilities already established by our partner. So the focus of Ascelia is to continue the dialogue with potential partners, and to ensure that all clients and their partners are ready to launch upon approval. So we are both excited and optimistic. About our launch preparations and our partnering opportunities. And also because almost all physicians tell us that they would like to use our exams when they are available on the market. So in summary, our drug addresses a well-defined unmet need and it represents an attractive commercial opportunity. Our focus is to ensure that our drug is ready for launch with a partner. And all our efforts to help patients and to launch the drug are well recognized by experts and partners in the industry. With this, I will hand over to Andreas Norlin to talk about Oncoral.

Andreas Norlin
18:30 - 21:01

Thank you, Julie. Yes. Let's move on to Oncoral. So Oncoral is a daily tablet formulation of irinotecan, a well-established intravenous chemotherapy. A daily tablet formulation enables a frequent low-dose dosing regimen that could offer potential advantages on both efficacy and safety, compared to the infrequent dosages of intravenous administration used today. We have completed a phase one study which demonstrated a promising safety profile and desired uptake of the drug after oral dosing, consistent with the daily dosing concept. We are now planning for taking Oncoral into clinical phase two. The objective is to generate clinical proof of efficacy data in metastatic gastric cancer in combination with lonsurf, another oral cancer treatment approved for gastric cancer. Animal data has demonstrated a synergistic effect of irinotecan when combined with lonsurf, which makes this combination very interesting. The planned phase two study is designed to study Oncoral against lonsurf alone. And the study will randomize approximately 100 patients and involves a clinical collaboration with Taiho Oncology, who will provide clinical advice and lonsurf for the study. We will initiate the oncology clinical work as soon as we have the financial resources to do so. Irinotecan is a well-established chemotherapy with recognized anti-tumor effect in solid tumors. Our strategy is to start development in gastric cancer, which is today a $3 billion market. For these patients, there is a high unmet medical need for improving outcomes, and there is an opportunity for an orphan indication. We also see opportunities for developing Oncoral in other solid tumor indications, where a daily dosing tablet formulation can demonstrate an attractive efficacy and safety profile. Irinotecan as an IV formulation is already approved in colorectal and pancreatic cancer. In addition, irinotecan is clinically demonstrated and recognized in guidelines for other cancer types. So we are assessing these opportunities as part of our ongoing strategic planning for Oncoral. So with that, back to Julie again.

Julie Waras Brogren
21:02 - 24:52

Yes. Thank you. And back to you. Now onto the financials and outlook. In Q1, our operating result was a loss, that is, total costs of 16.7 million krona. This is a slightly increased loss compared to Q4 2023, driven by the completion of the Orviglance reevaluation as well as NDA preparation activities. At the end of March 2024, we had 27 million krona in the bank. This includes the first tranche of the formal North financing announced in February. In April, we drew the remaining 15 million of this loan financing with the full financing now in place. We have a cash runway into Q2 2025 covering the completion of time-critical activities for the NDA. To wrap up our update today. We see substantial value creation opportunities ahead for Ascelia Pharma and for both of our orphan oncology assets in clinical development. We focus on three key objectives to create even more value for shareholders. With all the clinical trials, we're bringing to market a first-in-class diagnostic drug. Addressing an $800 million market for patients with high unmet needs, the first objective for Orviglance is a timely submission and approval with the optimal label. The key steps along the way are to complete the Orviglance clinical study report in early Q4. To reach conclusions from the pre-submission meeting with the FDA in Q1 next year, and to submit the NDA in the middle of next year. The second objective is to progress all the plans for commercialization for patients in need. The key activities are to continue advancing launch readiness by ensuring that all regulatory manufacturing and supply chain is ready for launch, and by working with medical experts, key payers, and patient groups, and other stakeholders who are instrumental for the adoption of Orviglance at launch. Our other track is to continue the dialogue and to enter into commercialization partnerships for Orviglance. The third objective is to develop the potential in the pipeline. We are excited about Oncoral and the planned phase two study, where we will evaluate it in combination with standard care. In our pipeline, we also have a second-generation Orviglance program that we would like to advance. Very limited activities and resources are allocated to these pipeline opportunities, but we look forward to accelerating these. Once financing is available. All in all, the strong headline results from Orviglance, announced earlier this month, marked the completion of the clinical development program and reinforce our confidence in the regulatory and commercial path ahead for Orviglance. We look very much forward to executing on the opportunities ahead for Orviglance and Ascelia Pharma in 2024 and beyond. This concludes our update for today. So, back to the operators.

Operator
24:57 - 25:28

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. And there are no phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
25:29 - 26:32

Yeah. Thank you everyone. Um, we have received some questions here. Um, and you are invited to also ask questions here, on this portal. So, um, the first question is, has the company been approached by any parties expressing interest in making a bid for the entire company or specifically for the rights? I think, uh, briefly speaking, we cannot really comment on that. What we have said is that our strategy is to find commercialization partners. And obviously, at the point in time where there is any, uh, firm announcement that is material, we will make those announcements. So we cannot comment on the activity level or the dialogue level at any point in time. Um, another question is, is GE Healthcare a potential partner for taking our claims to the market? Maybe Julie, you can comment on a specific company. But obviously it's general comments we can make.

Julie Waras Brogren
26:32 - 26:56

Yeah, I agree. We wouldn't comment on a specific company. But of course, the actors in the radiology, diagnostic drugs, and the gadolinium manufacturers, of course. God knows that potentially you could add more value to the portfolio. Among other potential profiles of companies here.

Magnus Corfitzen
26:59 - 27:17

There is another question here. Do you have any thoughts on the possibility of requesting a priority review from the FDA? And this is a dual question. It's part of it is regulatory and the other part is commercialization. Um, maybe Julie, you could provide an answer here.

Julie Waras Brogren
27:18 - 28:11

Sure. So a priority review is something we can consider when we submit the NDA and then the FDA would decide whether or not to grant this. A priority review means that the review timeline, usually ten months, is reduced to six months. So, uh, in the scenario of a six-month review timeline, what we need to consider before we apply is that we are absolutely sure we are ready to both answer the questions from the FDA with high quality during the review but also that we are ready with a full launch upon that approval. So, um, that's something we don't need to decide right now. Yeah.

Magnus Corfitzen
28:13 - 28:41

And just to complement. That's also something that would be a dialogue with, uh, most likely a potential partner, uh, in terms of their launch readiness, as Julie alludes to. Another question here is, could you provide any further insights or narrower estimates regarding your price of 3000 to 4500 dollars against those in the US? Judy. That's one for you.

Julie Waras Brogren
28:43 - 29:41

Yeah. So, uh, this pricing is based on, as I mentioned, tests with different types of payers in the US. And, and so that's how you end up with a range; essentially, we now have the full data. Uh, in the future, we'll have the label. And, and those are the elements that, that we need to narrow down on the more precise pricing at the end of the day. Um, it's going to be about finding the optimal balance between the volume we can address within the label and the price and value per dose. So the right time to narrow that is a little later in the process. But the key is, I think, that with all the data we have and the target product profile, the feedback is that we can obtain a very attractive price. Mm.

Magnus Corfitzen
29:45 - 30:14

Here's another question. So please discuss the key biopharma players that are relevant for consideration as potential partners for our clients and also share some of their current activities in the relevant space for diagnostic liver med products and deal history. In general terms, please describe your ongoing partner in discussions, status, aims, and plans. Outlook for 2024-2025. So a lot of things to cover. Um, usually start.

Julie Waras Brogren
30:15 - 33:30

Yeah. Uh, start in terms of the ongoing partnering discussions. Uh, as the question also alludes to, uh, that is an ongoing process where we have an understanding of the different profiles, which is a question here. And then, how does such a process evolve? Uh, first of all, we now have the headline data. So we are in a position to sort of, um, you can say, ramp up or intensify some of these discussions. So in terms of the process, I think that's a key thing: we can move from all the current data and the strategies we have to now having reduced the risk significantly with positive headline data. And also having a plan for the NDA submission. So there are some steps in the process that are instrumental for these partnering discussions. And then the other question is around who the key players are and what the deal history is. Um. The key players could be interested in a product like Oakland, where there's some kind of synergy in the commercial operations or strategy, and where Oakland is a meaningful contribution to their strategy. And so some of these synergies could be, you know, that they are distributing or they're commercializing to radiology departments for sure at hospitals or independent radiology clinics. So those are, of course, among these, the gadolinium manufacturers. Uh, but there could be other companies that are currently commercializing drugs within radiology. Uh, another angle to the synergies is that the overlap is a high-value drug for a well-defined small population. So a partner that understands the value and the mechanics in commercializing, you can say a high value, smaller volume drug is another area of synergies and of course also a profile of players. And then again, there are other, um, sort of. Similar types of synergies. For example, a partner who has a portfolio within oncology. So experts in kidney diseases would also be a partner where Orviglance could contribute to their portfolio. But I think that was enough about this. I don't know if you have something to add here in terms of the deal history that has been mentioned. We know that some of the large radiology players have been active in M&A, investments, and commercialization agreements on an ongoing basis. But I don't think it's our place to map out the deal history here. Um.

Magnus Corfitzen
33:31 - 33:52

Yeah, I think there are definitely transactions happening, especially in terms of later stage transactions that have been successful. And I think if we're thinking about specialized diagnostic groups, maybe just a couple of examples, like Blue Earth, which was acquired by Bracco.

Andreas Norlin
33:52 - 33:53

For.

Magnus Corfitzen
33:53 - 36:25

Around $450 million a couple of years ago. We also had Progenics being acquired by Lantheus. I think that's probably a. If I recall correctly. But that's probably just from memory. Like a $300 million transaction. And that drug is approaching blockbuster status for collectors today. So there are some very attractive transactions being made in this space for specialty diagnostic drugs that address a clear unmet medical need. So I think there are great opportunities, and as Julie Waras Brogren said and has presented also in our various investor updates, this is a focused commercial launch, which means that it's not a huge team that is required to successfully penetrate the majority of the US market. And that opens up to the categories you mentioned in terms of radiology companies, but also other companies within oncology, nephrology, etc. So I think that gives us a broad range of opportunities with companies that could be potentially very good fits to Ascelia Pharma. So we're very excited about this. And you could say with the phase 3 data, that's a good component of having a partnership discussion. Yes. Another question that is commonly raised is once financing is available, which we have mentioned repeatedly. This could be interpreted by skeptics as if you expect to run another financing round, but it seems more likely that you would generate the required income from partnering. Please comment. So I can have a stab at this. Our plan is to make sure that we meet the most successful value inflection points. And looking back, it has been to complete the Sparql study. It has now been completed. We have very successful data. Going forward, the NDA submission process and securing partnerships are key activities. Given the current balance sheet, it would not be prudent to initiate phase two or move forward significantly with second-generation projects. We refer to this because it represents an opportunity for investment which we believe will yield a very attractive return.

Unknown 1
36:25 - 36:25

We are

Magnus Corfitzen
36:25 - 38:04

very conscious of managing the balance sheet and the costs. Therefore, we see this as an opportunity. We will invest once the funding is available. We have also stated that we are exploring various sources of capital and are keeping all options open. We would expect that with this kind of Phase 3 data, a partnership deal would bring cash to the company. That could be a financial driver or could involve financial markets. But we don't rule anything out. We're not saying we want to do one thing or the other, but we have clearly stated that we want to bring in commercial partners for Orviglance. Hopefully, that clarifies any uncertainty regarding financing. This was the final question. So, thank you everybody for joining the call in 2024 for Ascelia. We are very excited about the data and the results of this pivotal study. It has taken a bit longer than originally anticipated, but we are here at the end. We have very strong Phase 3 data and are excited about moving the asset forward toward patients in the regulatory phase, and also preparing for launch readiness in terms of supply, stakeholder engagement, and finding commercialization partners. So with that, I'd like to thank everybody for participating and wish you all a wonderful day.

Julie Waras Brogren
38:06 - 38:07

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…